Takahashi, Naoto http://orcid.org/0000-0002-6758-3787
,
Tauchi, Tetsuzo
Kitamura, Kunio
Miyamura, Koichi
Saburi, Yoshio
Hatta, Yoshihiro
Miyata, Yasuhiko
Kobayashi, Shinichi
Usuki, Kensuke
Matsumura, Itaru
Minami, Yosuke
Usui, Noriko
Fukuda, Tetsuya
Takada, Satoru
Ishikawa, Maho
Fujimaki, Katsumichi
Gomyo, Hiroshi
Sasaki, Osamu
Ohishi, Kohshi
Miyake, Takaaki
Imai, Kiyotoshi
Suzushima, Hitoshi
Mitsui, Hideki
Togitani, Kazuto
Kiguchi, Toru
Atsuta, Yoshiko
Ohtake, Shigeki
Ohnishi, Kazunori
Kobayashi, Yukio
Kiyoi, Hitoshi
Miyazaki, Yasushi
Naoe, Tomoki
Funding for this research was provided by:
Japan Agency for Medical Research and Development (15ck0106189h0001, 16ck0106189h0002, 17ck0106189h0003)
Article History
Received: 8 August 2017
Revised: 12 September 2017
Accepted: 12 September 2017
First Online: 19 September 2017
Compliance with ethical standards
:
: Naoto Takahashi reports grants from Japan Agency for Medical Research and Development, non-financial support from Sysmex Co., Ltd., personal fees from NPO JALSG, during the conduct of the study; grants and personal fees from Novartis Pharma K.K., grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants and personal fees from Pfizer Japan Inc., personal fees from Bristol-Myers Squibb K. K., outside the submitted work. Tetsuzo Tauchi reports grants and other from Novartis Pharma K.K., grants and other from Pfizer Japan Inc., other from Bristol-Myers Squibb K. K., other from Otsuka Pharmaceutical Co., Ltd., during the conduct of the study. Koichi Miyamura reports personal fees from Novartis Pharma K.K., personal fees from Otsuka Pharmaceutical Co., Ltd., personal fees from Bristol-Myers Squibb K. K., personal fees from Pfizer Japan Inc., outside the submitted work. Kensuke Usuki reports personal fees from Novartis Pharma K.K., grants from Fujimoto Pharmaceutical, grants from Otsuka Pharmaceutical Co., Ltd., grants from Sumitomo Dainippon Pharma Co., Ltd., grants from Kyowa Hakko Kirin Co., Ltd., grants from Daiichi Sankyo Co., Ltd., outside the submitted work. Itaru Matsumura reports personal fees from Novartis Pharma K.K., personal fees from Bristol-Myers Squibb K. K., personal fees from Pfizer Japan Inc., personal fees from Otsuka Pharmaceutical Co., Ltd., during the conduct of the study. Yosuke Minami reports grants from Kyowa Hakko Kirin Co., Ltd., grants from Novartis Pharma K.K., grants from Bristol-Myers Squibb K. K., outside the submitted work. Noriko Usui reports personal fees from CIMIC Co., Ltd., personal fees from Takeda Bio Development Center, personal fees from Lilly Japan, personal fees from Pfizer Japan Inc., grants from Pfizer Japan Inc., personal fees from Nippon Boehringer Ingelheim Co., Ltd., grants from Sysmex Co., Ltd., personal fees from Jansen Pharm Co, Ltd., personal fees from Zenyaku Kogyo Co, Ltd., personal fees from Kyowa Hakko Kirin Co., Ltd., grants from Kyowa Hakko Kirin Co., Ltd., personal fees from Otsuka Pharmaceutical Co., Ltd., personal fees from Celgene K. K., personal fees from SymBio Pharm Co, Ltd., personal fees from Huya Bioscience International, personal fees from Astellas Pharma Inc., personal fees from Chugai Pharmaceutical Co. Ltd., grants from Bristol-Myers Squibb K. K., personal fees from Bristol-Myers Squibb K. K., grants from Novartis Pharma K.K., grants from Nippon Shinyaku Co. Ltd., grants from Fujimoto Pharmaceutical, grants from Celgene K. K., outside the submitted work. Tetsuya Fukuda reports personal fees from Novartis Pharma K.K., outside the submitted work. Yoshiko Atsuta reports personal fees and other from Otsuka Pharmaceutical Co., Ltd., personal fees and other from Bristol-Myers Squibb K. K., personal fees from Mochida Pharmaceutical Co., Ltd., personal fees from Kyowa Hakko Kirin Co., Ltd., outside the submitted work. Yukio Kobayashi reports personal fees from Pfizer Japan Inc., personal fees from Otsuka Pharmaceutical Co., Ltd., personal fees from Daiichi Sankyo Co., Ltd., personal fees from CIMIC Co., Ltd., outside the submitted work. Hitoshi Kiyoi reports grants from Japan Agency for Medical Research and Development, during the conduct of the study; grants from Chugai Pharmaceutical Co. Ltd., grants and personal fees from Bristol-Myers Squibb K. K., grants from Kyowa Hakko Kirin Co. Ltd., grants from FUJIFILM Corporation, grants from Nippon Boehringer Ingelheim Co., Ltd., grants and personal fees from Astellas Pharma Inc., grants from Celgene K. K., personal fees from Daiichi Sankyo Co. Ltd., grants and personal fees from Pfizer Japan Inc., grants from Nippon Shinyaku Co. Ltd., grants from Eisai Co. Ltd., grants from Takeda Pharmaceutical Co. Ltd., grants from Ono Pharmaceutical Co. Ltd., grants from Japan Blood Products Organization, outside the submitted work. Yasushi Miyazaki reports personal fees from Sumitomo Dainippon Pharma Co., Ltd., grants and personal fees from Kyowa Hakko Kirin Co., Ltd., personal fees from Novartis Pharma K.K., personal fees from Celgene K. K., personal fees from Shinbio, grants from Chugai Pharmaceutical Co. Ltd., grants from Takeda Pharmaceutical Co. Ltd., outside the submitted work. Tomoki Naoe reports grants from Sumitomo Dainippon Pharma Co., Ltd., grants from Fujifilm Corporation, grants from Astellas Pharma Inc., personal fees from Nippon Boehringer Ingelheim Co., Ltd., grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants from Toyoma Chemical Co., Ltd., outside the submitted work; In addition, TN has a patent Fujifilm Corporation pending. The other authors declare that they have no conflict of interest.